Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Navivumab

Catalog No. T77094 Copy Product Info
🥰Excellent
Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1].

Navivumab

Copy Product Info
🥰Excellent
Catalog No. T77094

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1].

Navivumab
Cas No. 1443004-16-7
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$2472-4 weeks2-4 weeks
5 mg$6472-4 weeks2-4 weeks
10 mg$9872-4 weeks2-4 weeks
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1].
Reactivity
Virus
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
TargetthehemagglutininHAoftheinfluenzaAvirus
Chemical Properties
Cas No.1443004-16-7
Storage & Solubility Information
Storage-20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Navivumab | purchase Navivumab | Navivumab cost | order Navivumab